PSTX (Poseida Therapeutics) Market Cap : $925.9 Mil (As of Mar. 20, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Poseida Therapeutics's share price for the quarter that ended in Sep. 2024 was $2.86. Poseida Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 97.4 Mil. Therefore, Poseida Therapeutics's market cap for the quarter that ended in Sep. 2024 was $278.6 Mil.

Poseida Therapeutics's quarterly market cap declined from Mar. 2024 ($308.8 Mil) to Jun. 2024 ($283.5 Mil) and declined from Jun. 2024 ($283.5 Mil) to Sep. 2024 ($278.6 Mil).

Poseida Therapeutics's annual market cap increased from Dec. 2021 ($425.8 Mil) to Dec. 2022 ($455.6 Mil) but then declined from Dec. 2022 ($455.6 Mil) to Dec. 2023 ($321.3 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Poseida Therapeutics's Enterprise Value for Today is $777.8 Mil.

Poseida Therapeutics Market Cap Historical Data

The historical data trend for Poseida Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poseida Therapeutics Market Cap Chart

Poseida Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

678.62

425.79

455.61

321.34

Poseida Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Market Cap	Get a 7-Day Free Trial															227.47	321.34	308.79	283.48	278.60

Competitive Comparison of Poseida Therapeutics's Market Cap

For the Biotechnology subindustry, Poseida Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poseida Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Poseida Therapeutics's Market Cap falls into.

Poseida Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Poseida Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$3.36	*	95.637
	=	$321.3

Poseida Therapeutics's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )	=	Share Price (Q: Sep. 2024 )	*	Shares Outstanding (EOP) (Q: Sep. 2024 )
	=	$2.86	*	97.412
	=	$278.6

Poseida Therapeutics (NAS:PSTX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Poseida Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Poseida Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (NAS:PSTX) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.poseida.com

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Executives

Mark J Gergen	director, officer: President and CBO	C/O MIRATI THERAPEUTICS INC., 9393 TOWN CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
John P. Schmid	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Luke Corning	director	614 DAVIS STREET, EVANSTON IL 60201
Marcea Bland Lloyd	director	9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Cynthia Collins	director	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Rafael Amado	director	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Kristin Yarema	officer: President, Cell Therapy	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Malin Life Sciences Holdings Ltd	10 percent owner	2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
Eric Ostertag	director, 10 percent owner, officer: Chief Executive Officer	C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Kerry D. Ingalls	officer: Chief Operating Officer	C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Brent Warner	officer: President, Gene Therapy	C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Matthew A. Spear	officer: Chief Medical Officer	C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Harry J Leonhardt	officer: GC & Chief Compliance Officer	C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
David Hirsch	director	C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025